SEATTLE, WA--(Marketwire - Jan 18, 2013) - Atossa Genetics, Inc. (
Mr. Guse stated, "I look forward to participating in this prestigious conference and presenting the Atossa Genetics story to investors. My presentation will include a discussion of the recently announced national rollout of our ForeCYTE Breast Health Test, further commercialization of our ArgusCYTE Breast Health Test, advancement of two additional tests and of the planned clinical development of our intraductal therapeutic for treatment of pre-cancerous cellular changes as a means to potentially prevent breast cancer."
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (
The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission and other filings with the SEC. All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
- breast cancer